Relation of Statin Nonadherence and Treatment Intensification

被引:27
作者
Pittman, Donald G. [1 ]
Fenton, Cynthia [2 ]
Chen, William [1 ]
Haffner, Steven
Pendergrass, Merri [1 ,3 ]
机构
[1] Express Scripts, St Louis, MO 63121 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Arizona, Tucson, AZ USA
关键词
MEDICATION ADHERENCE; THERAPY; CHOLESTEROL; CARE; OUTCOMES; INERTIA; COSTS;
D O I
10.1016/j.amjcard.2012.07.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Failure to intensify medication and failure to adhere to medication have been shown to contribute to suboptimal low-density lipoprotein cholesterol goal attainment. To examine whether nonadherence to statins in 126,903 patients on stable statin therapy is associated with subsequent treatment intensification, we conducted a retrospective analysis using an integrated pharmacy and medical claims database. Pharmacy claims were analyzed to determine whether nonadherence, as measured by proportion of days covered on statins <80%, was associated with intensification of statin treatment over a 360-day follow-up. Of 11,361 patients who had treatment intensification, 44% were previously nonadherent to statins. Patients whose treatment was intensified had slightly lower adherence to statin therapy than those without intensification (76% vs 78%, p <0.0001) and were more likely to be nonadherent as defined by proportion of days covered <80% (44% vs 37%, p <0.0001). After controlling for confounding factors, patients nonadherent to statins were 30% more likely to have treatment intensification compared to adherent patients (odds ratio 1.30, 95% confidence interval 1.25 to 1.36). In addition, patients with statin intensification were more likely to be younger, women, and have coronary artery disease, diabetes, hypertension, dyslipidemia, stroke, peripheral arterial disease, heart failure, or depression. Primary care physicians were more likely to escalate therapy than cardiologists. In conclusion, nearly 1/2 of patients with therapy escalation were nonadherent to statins. Clinicians should inquire about adherence and consider adherence before escalating statin therapy. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:1459-1463)
引用
收藏
页码:1459 / 1463
页数:5
相关论文
共 23 条
  • [1] Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
  • [2] Methods for evaluation of medication adherence and persistence using automated databases
    Andrade, Susan E.
    Kahler, Kristijan H.
    Frech, Feride
    Chan, K. Arnold
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (08) : 565 - 574
  • [3] Determinants of the differences in LDL-cholesterol after initiation of statin treatment
    Caspard, H
    Chan, AK
    Walker, AM
    [J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (01) : 21 - 26
  • [4] Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice
    Frolkis, JP
    Pearce, GL
    Nambi, V
    Minor, S
    Sprecher, DL
    [J]. AMERICAN JOURNAL OF MEDICINE, 2002, 113 (08) : 625 - 629
  • [5] Goldberg KC, 2007, AM J MANAG CARE, V13, P530
  • [6] Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management
    Grant, Richard
    Adams, Alyce S.
    Trinacty, Connie Mah
    Zhang, Fang
    Kleinman, Ken
    Soumerai, Stephen B.
    Meigs, James B.
    Ross-Degnan, Dennis
    [J]. DIABETES CARE, 2007, 30 (04) : 807 - 812
  • [7] Medication adherence before an increase in antihypertensive therapy: A cohort study using pharmacy claims data
    Grant, RW
    Singer, DE
    Meigs, JB
    [J]. CLINICAL THERAPEUTICS, 2005, 27 (06) : 773 - 781
  • [8] Quality of diabetes care in US academic medical centers - Low rates of medical regimen change
    Grant, RW
    Buse, JB
    Meigs, JB
    [J]. DIABETES CARE, 2005, 28 (02) : 337 - 342
  • [9] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, R
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Cleeman, JI
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    Keller, SA
    Jehle, AJ
    [J]. CIRCULATION, 2002, 106 (25) : 3143 - 3421
  • [10] Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Grundy, SM
    Cleeman, JI
    Merz, CNB
    Brewer, HB
    Clark, LT
    Hunninghake, DB
    Pasternak, RC
    Smith, SC
    Stone, NJ
    [J]. CIRCULATION, 2004, 110 (02) : 227 - 239